Quick Facts
FONT-SIZE Plus   Neg
Share SHARE
mail  E-MAIL

Shire's DERMAGRAFT Approved In Canada For Treating Diabetic Foot Ulcers

9/5/2012 7:35 AM ET

Shire Plc (SHP.L, SHPG) said its lead regenerative medicine product, DERMAGRAFT (human fibroblast-derived dermal substitute) secured regulatory approval from Health Canada as a class IV medical device for the treatment of diabetic foot ulcers (DFUs), a complication of diabetes.

Shire Regenerative Medicine plans to make DERMAGRAFT available in Canada in the first quarter of 2013, and will leverage Shire's current infrastructure and commercial knowledge of the Canadian healthcare system.

Click here to receive FREE breaking news email alerts for Shire plc and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Stocks continue to show a lack of direction in mid-day trading on Thursday, extending the lackluster performance seen earlier in the session. The major averages have spent the day bouncing back and forth across the unchanged line. After speaking with President Barack Obama by phone about stalled immigration reform legislation on Wednesday, House Majority Leader Eric Cantor, R-Virg., claimed the president still does not understand how to work with the Republican-controlled House. Growth in Philadelphia-area manufacturing activity has accelerated by much more than anticipated in the month of April, according to the results of the Federal Reserve Bank of Philadelphia's Business Outlook Survey released on Thursday. The Philly Fed said its diffusion index of current activity climbed to 16.6 in April from 9.0 in March, with a positive reading indicating growth.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.